Form 4: Acrivon Legal Officer's Routine Stock Withholding

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a disposition of 659 common shares to cover tax withholdings on restricted stock unit vesting.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on January 17, 2026.
• The transaction involved the disposition of 659 shares of Acrivon Therapeutics common stock.
• These shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The price per share for the disposition was $1.98.
• Following this transaction, Mary Miller beneficially owns 33,896 shares of Acrivon Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the withholding of shares for tax purposes upon RSU vesting, which is a neutral event for company operations and valuation.

Positives

• The vesting of restricted stock units indicates the company's employee compensation and retention mechanisms are functioning as intended.

Negatives

• A reduction of 659 common shares from direct beneficial ownership by a key executive.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: Experience negligible dilution due to the routine withholding of shares by the issuer for tax purposes.
• Employees: The vesting of RSUs and subsequent tax withholding confirms the functioning of the company's compensation plan, which can positively impact employee morale and retention.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares by an insider to cover tax obligations related to restricted stock unit vesting. Such a transaction is a standard part of executive compensation and does not typically indicate a change in the company's operational performance or strategic direction, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Acrivon Therapeutics, ACRV, Form 4, insider transaction, stock withholding, restricted stock units, RSU, tax withholding, Mary Miller, Chief Legal Officer